Anixa Biosciences, Inc. (FRA:CY71)

Anixa Biosciences Income Statement

Financials in millions USD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul 31, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020
Revenue	-	-	0.21	-	0.51	-
Cost of Revenue	-	-	0.16	-	0.39	-
Gross Profit	-	-	0.05	-	0.13	-
Selling, General & Admin	6.58	7.44	6.29	7.17	7.07	5.93
Research & Development	5.41	6.4	4.77	6.7	6.19	4.38
Operating Expenses	11.99	13.83	11.06	13.88	13.26	10.32
Operating Income	-11.99	-13.83	-11.01	-13.88	-13.14	-10.32
Interest & Investment Income	0.77	1.13	1.08	0.1	0	0.03
EBT Excluding Unusual Items	-11.22	-12.7	-9.93	-13.77	-13.13	-10.28
Gain (Loss) on Sale of Assets	-	-	-	-	0.01	-0.15
Other Unusual Items	-	-	-	-	-	0.34
Pretax Income	-11.22	-12.7	-9.93	-13.77	-13.13	-10.09
Earnings From Continuing Operations	-11.22	-12.7	-9.93	-13.77	-13.13	-10.09
Minority Interest in Earnings	0.1	0.14	0.12	0.18	0.17	0.07
Net Income	-11.12	-12.55	-9.81	-13.6	-12.95	-10.02
Net Income to Common	-11.12	-12.55	-9.81	-13.6	-12.95	-10.02
Shares Outstanding (Basic)	32	32	31	30	29	22
Shares Outstanding (Diluted)	32	32	31	30	29	22
Shares Change (YoY)	2.02%	2.96%	1.99%	6.28%	28.57%	12.33%
EPS (Basic)	-0.34	-0.39	-0.32	-0.45	-0.45	-0.45
EPS (Diluted)	-0.34	-0.39	-0.32	-0.45	-0.45	-0.45
Free Cash Flow	-6.85	-7.34	-6.21	-6.49	-4.94	-6.19
Free Cash Flow Per Share	-0.21	-0.23	-0.20	-0.21	-0.17	-0.28
Gross Margin	-	-	23.33%	-	24.80%	-
Operating Margin	-	-	-5243.33%	-	-2565.63%	-
Profit Margin	-	-	-4671.91%	-	-2530.08%	-
Free Cash Flow Margin	-	-	-2956.67%	-	-964.45%	-
EBITDA	-	-	-	-	-13.1	-10.28
D&A For EBITDA	-	-	-	-	0.04	0.04
EBIT	-11.99	-13.83	-11.01	-13.88	-13.14	-10.32

Source: S&P Global Market Intelligence. Standard template. Financial Sources.